Timothy Jenkins
@TimothyPJenkins
Head of Data Science and Assistant Prof at DTU Bioengineering with a keen interest in antibody discovery, de-novo protein design, ML, and next-gen therapeutics.
At @affinityaibio we’re moving from “finders keepers” to “designers binders”, one generative model at a time. If you could have a binder to anything, what would it be? (Proteins, obscure signalling pathways, that one reviewer who never gets back to you…;)
We’re rethinking what a binding reagent can be. Most antibodies weren’t designed, they were discovered. At AffinityAI, we’re flipping that logic: we build binders from first principles, guided by generative AI. What targets would you be interested in having a binder to?
At AffinityAI, we combine Danish design sensibilities with precision molecular engineering. Elegant. Efficient. Engineered to bind. 🧬 Discover how we’re reshaping molecular function: affinityai.bio
Another Huge, insane cancer Breakthrough A new AI based method can produce specially designed proteins in just a few weeks that can arm the T cells in the body's immune system to attack and kill cancer cells Researchers from the Technical University of Denmark and the Scripps…
De Novo-Designed pMHC Binders Facilitate T Cell–Mediated Cytotoxicity Toward Cancer Cells @ScienceMagazine 1. A groundbreaking study presents a rapid de novo design platform for minibinders (miBds) targeting cancer-associated peptide-bound major histocompatibility complex (pMHC)…
Thrilled to share our new paper in @ScienceMagazine! 💥 We developed a computational platform to design tiny 'minibinders' from scratch that can guide T cells to kill cancer cells. This is proof-of-concept for targeting intracellular cancer antigens with a new modality! 🎯
While I’m bouncing between emails and desperately waiting for my holiday, it’s good to know at least something in the lab is holding it together Thermal stability might not be glamorous, but it’s underrated Designerbodies: even when things get heated, still doing their job ;)
Whether you're on holiday 🏖️ or still in the lab 🧪 trying to keep cool, at least one thing isn't melting: our DesignerBodies. Generatively designed. Thermally stable ❄️ Reliable reagents that don’t need a break 💪 #ProteinDesign #AI #Biotech
🧬 In March, we published our research for InstaNovo and InstaNovo+ in @NatMachIntell, our diffusion-powered ‘de novo’ peptide sequencing models built to uncover the secrets of the human proteome. bit.ly/3XBeJFh
📆 Six months, four publications, one cover. We’re halfway through the year and InstaDeep research is powering ahead with multiple boundary-pushing papers published in the @NaturePortfolio! Catch up on the highlights below 🔽
Great to see AffinityAI represented by @esperdet and Oliver Morell at the @DTUtweet Startup Day 💪 Lots of interest in what we’re building, especially the fact that we deliver #real #reagents rather than just #AI predictions. Excited for what's to come! @DTUSkylab
Great energy at @DTUtweet Startup Day 🎉 Big thanks to @DTUSkylab for bringing together researchers, investors, and innovators. We had a blast sharing what we're building at AffinityAI. #AffinityAI #DTUSkylab #StartupLife
Excited to co-found and help lead @IMPRINTlabs—a focused effort to decode the immune system’s memory through cutting-edge computation and experimentation. Grateful to be on this journey with an exceptional team.
🧵 Today, IMPRINT, a pioneering new nonprofit initiative, is announcing $15 million in philanthropic funding to advance our work to decode the body's immune memory and uncover the causes of chronic diseases. imprint.org/press-release-… With teams in Europe and North America, we are…
🚨 We’re hiring a PhD student! 🚨 Join us at @DTUbioengineer + collaborators @MessoudAshina & @h_ashina + @esperdet to bring preventative migraine therapeutics from 💻 to 🧠. 🔗 Apply: lnkd.in/dCRU_EN3 🔍 Project: lnkd.in/dbpi8MwX
